1
|
Alba-Arbalat S, Solana E, Lopez-Soley E, Camos-Carreras A, Martinez-Heras E, Vivó F, Pulido-Valdeolivas I, Andorra M, Sepulveda M, Cabrera JM, Fonseca E, Calvi A, Alcubierre R, Dotti-Boada M, Saiz A, Martinez-Lapiscina EH, Villoslada P, Blanco Y, Sanchez-Dalmau B, Llufriu S. Predictive value of retinal atrophy for cognitive decline across disease duration in multiple sclerosis. J Neurol Neurosurg Psychiatry 2024; 95:419-425. [PMID: 37989566 DOI: 10.1136/jnnp-2023-332332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 10/23/2023] [Indexed: 11/23/2023]
Abstract
BACKGROUND We investigated the association between changes in retinal thickness and cognition in people with MS (PwMS), exploring the predictive value of optical coherence tomography (OCT) markers of neuroaxonal damage for global cognitive decline at different periods of disease. METHOD We quantified the peripapillary retinal nerve fibre (pRFNL) and ganglion cell-inner plexiform (GCIPL) layers thicknesses of 207 PwMS and performed neuropsychological evaluations. The cohort was divided based on disease duration (≤5 years or >5 years). We studied associations between changes in OCT and cognition over time, and assessed the risk of cognitive decline of a pRFNL≤88 µm or GCIPL≤77 µm and its predictive value. RESULTS Changes in pRFNL and GCIPL thickness over 3.2 years were associated with evolution of cognitive scores, in the entire cohort and in patients with more than 5 years of disease (p<0.01). Changes in cognition were related to less use of disease-modifying drugs, but not OCT metrics in PwMS within 5 years of onset. A pRFNL≤88 µm was associated with earlier cognitive disability (3.7 vs 9.9 years) and higher risk of cognitive deterioration (HR=1.64, p=0.022). A GCIPL≤77 µm was not associated with a higher risk of cognitive decline, but a trend was observed at ≤91.5 µm in PwMS with longer disease (HR=1.81, p=0.061). CONCLUSIONS The progressive retinal thinning is related to cognitive decline, indicating that cognitive dysfunction is a late manifestation of accumulated neuroaxonal damage. Quantifying the pRFNL aids in identifying individuals at risk of cognitive dysfunction.
Collapse
Affiliation(s)
- Salut Alba-Arbalat
- Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | - Elisabeth Solana
- Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | - Elisabet Lopez-Soley
- Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | | | - Eloy Martinez-Heras
- Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | - Francesc Vivó
- Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | - Irene Pulido-Valdeolivas
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | - Magi Andorra
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | - Maria Sepulveda
- Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | - Jose María Cabrera
- Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | - Elianet Fonseca
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
- Neurology Department, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Alberto Calvi
- Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | - Rafel Alcubierre
- Ophthalmology Department, Hospital Clinic de Barcelona, Barcelona, Spain
| | - Marina Dotti-Boada
- Ophthalmology Department, Hospital Clinic de Barcelona, Barcelona, Spain
| | - Albert Saiz
- Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | - Elena H Martinez-Lapiscina
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | - Pablo Villoslada
- Department of Neurosciences, Hospital del Mar Medical Research Institute, Barcelona, Spain
| | - Yolanda Blanco
- Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| | | | - Sara Llufriu
- Neuroimmunology and Multiple Sclerosis Unit, Hospital Clinic de Barcelona, Barcelona, Spain
- Laboratory of Advanced Imaging in Neuroimmunological Diseases, Fundacio Recerca Clinic Barcelona -IDIBAPS, Barcelona, Spain
| |
Collapse
|
2
|
Fernández RS, Crivelli L, Pedreira ME, Allegri RF, Correale J. Computational basis of decision-making impairment in multiple sclerosis. Mult Scler 2021; 28:1267-1276. [PMID: 34931933 DOI: 10.1177/13524585211059308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Multiple sclerosis (MS) is commonly associated with decision-making, neurocognitive impairments, and mood and motivational symptoms. However, their relationship may be obscured by traditional scoring methods. OBJECTIVES To study the computational basis underlying decision-making impairments in MS and their interaction with neurocognitive and neuropsychiatric measures. METHODS Twenty-nine MS patients and 26 matched control subjects completed a computer version of the Iowa Gambling Task (IGT). Participants underwent neurocognitive evaluation using an expanded version of the Brief Repeatable Battery. Hierarchical Bayesian Analysis was used to estimate three established computational models to compare parameters between groups. RESULTS Patients showed increased learning rate and reduced loss-aversion during decision-making relative to control subjects. These alterations were associated with: (1) reduced net gains in the IGT; (2) processing speed, executive functioning and memory impairments; and (3) higher levels of depression and current apathy. CONCLUSION Decision-making deficits in MS patients could be described by the interplay between latent computational processes, neurocognitive impairments, and mood/motivational symptoms.
Collapse
Affiliation(s)
- Rodrigo S Fernández
- Instituto de Fisiología, Biología Molecular y Neurociencias (IFIBYNE-CONICET), Ciudad de Buenos Aires, Argentina/Laboratorio de Neurociencia de la Memoria, IFIBYNE-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina
| | - Lucia Crivelli
- Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology, Fleni, Buenos Aires, Argentina/Department of Neurology, Fleni, Buenos Aires, Argentina
| | - María E Pedreira
- Instituto de Fisiología, Biología Molecular y Neurociencias (IFIBYNE-CONICET), Ciudad de Buenos Aires, Argentina/Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina
| | - Ricardo F Allegri
- Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology, Fleni, Buenos Aires, Argentina/Department of Neurology, Fleni, Buenos Aires, Argentina/Universidad de la Costa (CUC), Barranquilla, Colombia
| | | |
Collapse
|
3
|
Kopanitsa MV, Lehtimäki KK, Forsman M, Suhonen A, Koponen J, Piiponniemi TO, Kärkkäinen AM, Pavlidi P, Shatillo A, Sweeney PJ, Merenlender-Wagner A, Kaye J, Orbach A, Nurmi A. Cognitive disturbances in the cuprizone model of multiple sclerosis. GENES BRAIN AND BEHAVIOR 2020; 20:e12663. [PMID: 32372528 DOI: 10.1111/gbb.12663] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/21/2019] [Revised: 04/29/2020] [Accepted: 04/29/2020] [Indexed: 12/19/2022]
Abstract
Cognitive problems frequently accompany neurological manifestations of multiple sclerosis (MS). However, during screening of preclinical candidates, assessments of behaviour in mouse models of MS typically focus on locomotor activity. In the present study, we analysed cognitive behaviour of 9 to 10-week-old female C57Bl/6J mice orally administered with the toxin cuprizone that induces demyelination, a characteristic feature of MS. Animals received 400 mg/kg cuprizone daily for 2 or 4 weeks, and their performance was compared with that of vehicle-treated mice. Cuprizone-treated animals showed multiple deficits in short touchscreen-based operant tasks: they responded more slowly to visual stimuli, rewards and made more errors in a simple rule-learning task. In contextual/cued fear conditioning experiments, cuprizone-treated mice showed significantly lower levels of contextual freezing than vehicle-treated mice. Diffusion tensor imaging showed treatment-dependent changes in fractional anisotropy as well as in axial and mean diffusivities in different white matter areas. Lower values of fractional anisotropy and axial diffusivity in cuprizone-treated mice indicated developing demyelination and/or axonal damage. Several diffusion tensor imaging measurements correlated with learning parameters. Our results show that translational touchscreen operant tests and fear conditioning paradigms can reliably detect cognitive consequences of cuprizone treatment. The suggested experimental approach enables screening novel MS drug candidates in longitudinal experiments for their ability to improve pathological changes in brain structure and reverse cognitive deficits.
Collapse
Affiliation(s)
- Maksym V Kopanitsa
- Charles River Discovery Services, Kuopio, Finland.,UK Dementia Research Institute, Department of Brain Sciences, Imperial College, London, UK
| | | | | | - Ari Suhonen
- Charles River Discovery Services, Kuopio, Finland
| | - Juho Koponen
- Charles River Discovery Services, Kuopio, Finland
| | | | | | - Pavlina Pavlidi
- MSc Programme in Translational Neuroscience, Imperial College, London, UK
| | | | | | | | - Joel Kaye
- Teva Pharmaceutical Industries Ltd, Netanya, Israel
| | - Aric Orbach
- Teva Pharmaceutical Industries Ltd, Netanya, Israel
| | - Antti Nurmi
- Charles River Discovery Services, Kuopio, Finland
| |
Collapse
|
4
|
Cognitive ability and risk aversion: A systematic review and meta analysis. JUDGMENT AND DECISION MAKING 2019. [DOI: 10.1017/s1930297500004307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
AbstractAre highly intelligent people less risk averse? Over the last two decades scholars have argued the existence of a negative relationship between cognitive ability and risk aversion. Although numerous studies support this, the link between cognitive ability and risk aversion has not been found consistently. To shed new light on this topic, a systematic review and meta-analysis was conducted. A total of 97 studies were identified and included for meta-analysis in the domain of gains (N=90, 723), 41 in the mixed domain (N=50, 936), and 12 in the domain of losses (N=4, 544). Results indicate that there exists a weak, but significant negative relationship between cognitive ability and risk aversion in the domain of gains. However, no relationship was observed in the mixed domain or in the domain of losses. Several meta-regressions were performed to investigate the influence of moderator variables. None of the moderator variables were found to consistently influence the relationship between cognitive ability and risk aversion across the domain of gains, mixed and losses. Moreover, no significant difference was observed between males and females across all three domains. In conclusion, this systematic review and meta-analysis provides new evidence that the relationship between cognitive ability and risk aversion is domain specific and not as strong as suggested by some previous studies.
Collapse
|
5
|
Lavorgna L, Esposito S, Lanzillo R, Sparaco M, Ippolito D, Cocco E, Fenu G, Borriello G, De Mercanti S, Frau J, Capuano R, Trojsi F, Rosa L, Clerico M, Laroni A, Morra VB, Tedeschi G, Bonavita S. Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey. J Neurol 2019; 266:707-716. [PMID: 30649617 DOI: 10.1007/s00415-019-09193-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2018] [Revised: 12/21/2018] [Accepted: 01/08/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND Little is known about the influence of multiple sclerosis (MS) diagnosis on parenthood attitude in people with MS (pwMS). OBJECTIVE To investigate the impact of diagnosis, clinical features and external disease-related influences on parenthood decision-making in Italian pwMS. METHODS A web-based survey was posted on SMsocialnetwork.com to investigate clinical status, parenthood desire, influences on family planning, pregnancy outcomes, abortions and adoptions of pwMS. RESULTS 33/395 respondents never wanted to become parent because of MS ("anti-parenthood after diagnosis"). 362 declared to be in favor of parenthood. 51% pwMS having a child by the survey time had already received the MS diagnosis at first childbirth. The frequency of a second child in pwMS after diagnosis was 38% compared to 67% in people without yet MS diagnosis. 16% of pwMS were discouraged to become parent after diagnosis, mainly by medical personnel. In 71% of respondents, diagnosis did not delay the decision to become parent and only 39% were counseled by treating physician to plan pregnancy. Patients' distribution according to the clinical phenotype (exclusively relapsing vs exclusively progressive) showed a higher proportion of progressive patients in the "anti-parenthood after diagnosis" subgroup. CONCLUSION MS diagnosis impacted dramatically on the life project of 7% of pwMS that decided not to have children because of the disease and in pro-parenthood pwMS impacted especially on having the second child. Only a minority was counseled to plan pregnancy. A worse disease course driving to a progressive phenotype at survey time might have negatively impacted on parenthood desire.
Collapse
Affiliation(s)
- L Lavorgna
- First Division of Neurology, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy.
| | - S Esposito
- First Division of Neurology, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
| | - R Lanzillo
- Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II, Naples, Italy
| | - M Sparaco
- First Division of Neurology, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy
| | - D Ippolito
- First Division of Neurology, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy
| | - E Cocco
- Department of Medical Sciences and Public Health, Multiple Sclerosis Centre, Binaghi Hospital, University of Cagliari, Cagliari, Italy
| | - G Fenu
- Department of Medical Sciences and Public Health, Multiple Sclerosis Centre, Binaghi Hospital, University of Cagliari, Cagliari, Italy
| | - G Borriello
- Department of Neurology and Psychiatry, S. Andrea MS Center, Sapienza University, Rome, Italy
| | - S De Mercanti
- Clinical and Biological Sciences Department, University of Torino, Turin, Italy
| | - J Frau
- Department of Medical Sciences and Public Health, Multiple Sclerosis Centre, Binaghi Hospital, University of Cagliari, Cagliari, Italy
| | - R Capuano
- First Division of Neurology, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy
| | - F Trojsi
- First Division of Neurology, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy
| | - L Rosa
- Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II, Naples, Italy
| | - M Clerico
- Clinical and Biological Sciences Department, University of Torino, Turin, Italy
| | - A Laroni
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, IRCCS AOU San Martino-IST, University of Genoa, Genoa, Italy
| | - V Brescia Morra
- Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II, Naples, Italy
| | - G Tedeschi
- First Division of Neurology, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy
- Neurological Institute for Diagnosis and Care "Hermitage Capodimonte", MRI Center SUN-FISM, Naples, Italy
| | - S Bonavita
- First Division of Neurology, University of Campania Luigi Vanvitelli, Piazza Miraglia, 2, 80138, Naples, Italy
- Neurological Institute for Diagnosis and Care "Hermitage Capodimonte", MRI Center SUN-FISM, Naples, Italy
| |
Collapse
|
6
|
Rivalan M, Winter Y, Nachev V. Principles of Economic Rationality in Mice. Sci Rep 2017; 7:17441. [PMID: 29234113 PMCID: PMC5727109 DOI: 10.1038/s41598-017-17747-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Accepted: 11/30/2017] [Indexed: 11/08/2022] Open
Abstract
Humans and non-human animals frequently violate principles of economic rationality, such as transitivity, independence of irrelevant alternatives, and regularity. The conditions that lead to these violations are not completely understood. Here we report a study on mice tested in automated home-cage setups using rewards of drinking water. Rewards differed in one of two dimensions, volume or probability. Our results suggest that mouse choice conforms to the principles of economic rationality for options that differ along a single reward dimension. A psychometric analysis of mouse choices further revealed that mice responded more strongly to differences in probability than to differences in volume, despite equivalence in return rates. This study also demonstrates the synergistic effect between the principles of economic rationality and psychophysics in making quantitative predictions about choices of healthy laboratory mice. This opens up new possibilities for the analyses of multi-dimensional choice and the use of mice with cognitive impairments that may violate economic rationality.
Collapse
Affiliation(s)
- Marion Rivalan
- Department of Biology, Humboldt University, Philippstr. 13, Berlin, 10099, Germany
| | - York Winter
- Department of Biology, Humboldt University, Philippstr. 13, Berlin, 10099, Germany.
| | - Vladislav Nachev
- Department of Biology, Humboldt University, Philippstr. 13, Berlin, 10099, Germany.
| |
Collapse
|
7
|
Weygandt M, Wakonig K, Behrens J, Meyer-Arndt L, Söder E, Brandt AU, Bellmann-Strobl J, Ruprecht K, Gold SM, Haynes JD, Paul F. Brain activity, regional gray matter loss, and decision-making in multiple sclerosis. Mult Scler 2017; 24:1163-1173. [PMID: 28657480 DOI: 10.1177/1352458517717089] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Decision-making (DM) abilities deteriorate with multiple sclerosis (MS) disease progression which impairs everyday life and is thus clinically important. OBJECTIVE To investigate the underlying neurocognitive processes and their relation to regional gray matter (GM) loss induced by MS. METHODS We used a functional magnetic resonance imaging (fMRI) Iowa Gambling Task to measure DM-related brain activity in 36 MS patients and 21 healthy controls (HC). From this activity, we determined neural parameters of two cognitive stages, a deliberation ("choice") period preceding a choice and a post-choice ("feedback") stage reporting decision outcomes. These measures were related to DM separately in intact and damaged GM areas as determined by a voxel-based morphometry analysis. RESULTS Severely affected patients (with high lesion burden) showed worse DM-learning than HC ( t = -1.75, p = 0.045), moderately affected (low lesion burden) did not. Activity in the choice stage in intact insular ( t = 4.60, pFamily-Wise Error [FWE] corrected = 0.034), anterior cingulate ( t = 4.50, pFWE = 0.044), and dorsolateral prefrontal areas ( t = 4.43, pFWE = 0.049) and in insular areas with GM loss ( t = 3.78, pFWE = 0.011) was positively linked to DM performance across patients with severe tissue damage and HC. Furthermore, activity in intact orbitofrontal areas was positively linked to DM-learning during the feedback stage across these participants ( t = 4.49, pFWE = 0.032). During none of the stages, moderately affected patients showed higher activity than HC, which might have indicated preserved DM due to compensatory activity. CONCLUSION We identified dysregulated activity linked to impairment in specific cognitive stages of reward-related DM. The link of brain activity and impaired DM in areas with MS-induced GM loss suggests that this deficit might be tightly coupled to MS neuropathology.
Collapse
Affiliation(s)
- Martin Weygandt
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Excellence Cluster NeuroCure; 10117 Berlin, Germany / Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Berlin Center for Advanced Neuroimaging, Department of Neurology; 10117 Berlin, Germany / Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Bernstein Center for Computational Neuroscience; 10117 Berlin, Germany
| | - Katharina Wakonig
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Excellence Cluster NeuroCure; 10117 Berlin, Germany
| | - Janina Behrens
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Excellence Cluster NeuroCure; 10117 Berlin, Germany / Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Excellence Cluster NeuroCure; 10117 Berlin, Germany. / Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology; 10117 Berlin, Germany
| | - Lil Meyer-Arndt
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Excellence Cluster NeuroCure; 10117 Berlin, Germany
| | - Eveline Söder
- Department of Clinical Psychology and Psychotherapy, Institute of Psychology, University of Hamburg, Hamburg, Germany
| | - Alexander U Brandt
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Excellence Cluster NeuroCure; 10117 Berlin, Germany
| | - Judith Bellmann-Strobl
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Excellence Cluster NeuroCure; 10117 Berlin, Germany / Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, 13125 Berlin, Germany
| | - Klemens Ruprecht
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology; 10117 Berlin, Germany
| | - Stefan M Gold
- Charité - Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Center for Molecular Neurobiology, University Medical Center, 20251 Hamburg, Germany / Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin; 12203 Berlin, Germany
| | - John-Dylan Haynes
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Excellence Cluster NeuroCure; 10117 Berlin, Germany / Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Berlin Center for Advanced Neuroimaging, Department of Neurology; 10117 Berlin, Germany / Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Bernstein Center for Computational Neuroscience; 10117 Berlin, Germany
| | - Friedemann Paul
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Excellence Cluster NeuroCure; 10117 Berlin, Germany / Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology; 10117 Berlin, Germany / Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, 13125 Berlin, Germany
| |
Collapse
|